Market overview
The global drug discovery services market is worth USD 26.4 bn in 2026 and is forecast to reach USD 71.7 bn by 2036, growing at a 10.5% CAGR. United States is the largest country market and Medicinal and synthetic chemistry is the largest by service segment.
| Scope | Contract services that find and optimise drug candidates for pharmaceutical and biotech clients: target validation, screening, medicinal chemistry, biology, pharmacology and computational design. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 24.0 bn |
| Value 2026 | USD 26.4 bn |
| Value 2036 | USD 71.7 bn |
| CAGR 2026-2036 | 10.5% |
| Volume 2026 | 48.5 thousand projects |
| Volume 2036 | 108 thousand projects |
| Average price 2026 | USD 544,000 per project |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Drug Discovery Services market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 26.4 bn |
| 2027 | USD 29.2 bn |
| 2028 | USD 32.2 bn |
| 2029 | USD 35.6 bn |
| 2030 | USD 39.4 bn |
| 2031 | USD 43.5 bn |
| 2032 | USD 48.1 bn |
| 2033 | USD 53.1 bn |
| 2034 | USD 58.7 bn |
| 2035 | USD 64.8 bn |
| 2036 | USD 71.7 bn |
Drug Discovery Services market segmentation
By service
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Medicinal and synthetic chemistry | 28.0% | 23.5% | USD 7.4 bn | 8.6% |
| Biology and screening | 26.0% | 24.0% | USD 6.9 bn | 9.6% |
| ADME and pharmacology | 18.0% | 17.4% | USD 4.8 bn | 10.1% |
| Computational and AI-driven discovery | 12.0% | 22.3% | USD 3.2 bn | 17.6% |
| Other discovery services | 16.0% | 12.8% | USD 4.2 bn | 8.1% |
By therapy
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 36.0% | 38.3% | USD 9.5 bn | 11.2% |
| Neurology | 16.0% | 15.6% | USD 4.2 bn | 10.2% |
| Immunology | 14.0% | 14.3% | USD 3.7 bn | 10.7% |
| Infectious diseases | 10.0% | 8.5% | USD 2.6 bn | 8.7% |
| Metabolic and other | 24.0% | 23.4% | USD 6.3 bn | 10.2% |
By client
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Large pharma | 52.0% | 45.9% | USD 13.7 bn | 9.1% |
| Biotech | 38.0% | 46.0% | USD 10.0 bn | 12.6% |
| Academic and other | 10.0% | 8.1% | USD 2.6 bn | 8.1% |
By discovery phase
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Target identification and validation | 18.0% | 19.0% | USD 4.8 bn | 11.1% |
| Hit-to-lead | 26.0% | 25.0% | USD 6.9 bn | 10.1% |
| Lead optimisation | 32.0% | 30.0% | USD 8.4 bn | 9.8% |
| Candidate selection | 24.0% | 26.0% | USD 6.3 bn | 11.4% |
By delivery model
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Fee for service | 46.0% | 40.0% | USD 12.1 bn | 9.0% |
| Dedicated teams | 30.0% | 28.0% | USD 7.9 bn | 9.7% |
| Risk-sharing and milestone partnerships | 24.0% | 32.0% | USD 6.3 bn | 13.7% |
Top 25 countries for drug discovery services by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 96.0% of 2026 revenue and the 25 countries below together hold 98.9%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 12.1 bn | 46.0% | USD 31.6 bn | 10.0% |
| 2 | China | USD 3.2 bn | 12.0% | USD 10.7 bn | 13.0% |
| 3 | United Kingdom | USD 2.1 bn | 8.0% | USD 5.2 bn | 9.5% |
| 4 | Germany | USD 1.6 bn | 6.0% | USD 3.9 bn | 9.5% |
| 5 | India | USD 1.6 bn | 6.0% | USD 5.4 bn | 13.0% |
| 6 | Switzerland | USD 1.1 bn | 4.0% | USD 2.7 bn | 9.6% |
| 7 | France | USD 1.1 bn | 4.0% | USD 2.7 bn | 9.6% |
| 8 | Japan | USD 1.1 bn | 4.0% | USD 2.5 bn | 9.0% |
| 9 | Denmark | USD 792 mn | 3.0% | USD 2.1 bn | 10.1% |
| 10 | Canada | USD 792 mn | 3.0% | USD 2.1 bn | 10.1% |
| 11 | Netherlands | USD 87 mn | 0.3% | USD 222 mn | 9.8% |
| 12 | South Korea | USD 77 mn | 0.3% | USD 244 mn | 12.3% |
| 13 | Belgium | USD 66 mn | 0.2% | USD 172 mn | 10.1% |
| 14 | Singapore | USD 66 mn | 0.2% | USD 208 mn | 12.2% |
| 15 | Australia | USD 55 mn | 0.2% | USD 143 mn | 10.0% |
| 16 | Sweden | USD 55 mn | 0.2% | USD 143 mn | 10.0% |
| 17 | Israel | USD 55 mn | 0.2% | USD 143 mn | 10.0% |
| 18 | Spain | USD 42 mn | 0.2% | USD 115 mn | 10.5% |
| 19 | Italy | USD 42 mn | 0.2% | USD 115 mn | 10.5% |
| 20 | Ireland | USD 42 mn | 0.2% | USD 115 mn | 10.5% |
| 21 | Taiwan | USD 42 mn | 0.2% | USD 143 mn | 13.0% |
| 22 | Austria | USD 32 mn | 0.1% | USD 86 mn | 10.5% |
| 23 | Finland | USD 32 mn | 0.1% | USD 86 mn | 10.5% |
| 24 | Norway | USD 32 mn | 0.1% | USD 86 mn | 10.5% |
| 25 | Poland | USD 32 mn | 0.1% | USD 86 mn | 10.5% |
| Rest of world | USD 298 mn | 1.1% | USD 688 mn | 8.7% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- WuXi AppTec
- Charles River Laboratories
- Evotec
- Eurofins Discovery
- Pharmaron
- Thermo Fisher Scientific
- Labcorp
- Curia Global
Group 2: Regional and specialist players
- Schrodinger
- Sygnature Discovery
- Syngene International
- Aragen Life Sciences
- Sai Life Sciences
- Selvita
- Jubilant Biosys
- Concept Life Sciences
- Oncodesign Services
- Nuvisan
Group 3: Emerging and niche players
- Insilico Medicine
- Domainex
- Aurigene
- XtalPi
- Enamine
- ChemPartner
- Charnwood Molecular
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the drug discovery services market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.5% is calculated from the resulting values.
The market is divided by service, by therapy, by client, by discovery phase, by delivery model. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the drug discovery services market?
The global drug discovery services market is estimated at USD 24.0 bn in 2025 and USD 26.4 bn in 2026.
How fast will the drug discovery services market grow?
It is forecast to reach USD 71.7 bn by 2036, a compound annual growth rate of 10.5% from 2026, an increase of USD 45.3 bn.
Which country is the largest market for drug discovery services?
United States is the largest market by revenue at USD 12.1 bn in 2026, 46.0% of the global total. The three largest countries together hold 66.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 13.0% a year from 2026 to 2036.
Which drug discovery services segment is largest?
In the by service split, Medicinal and synthetic chemistry is the largest segment with 28.0% of 2026 revenue.
Who are the leading drug discovery services companies?
Global leaders include WuXi AppTec, Charles River Laboratories, Evotec, Eurofins Discovery.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Wound CareUSD 26.5 bn · 6.0% CAGR
- Remote Patient MonitoringUSD 25.7 bn · 16.0% CAGR
- Cell CultureUSD 23.9 bn · 8.0% CAGR
- Ocular Drug DeliveryUSD 29.7 bn · 6.0% CAGR
- Oral Drug DeliveryUSD 22.6 bn · 7.5% CAGR
- Regenerative MedicineUSD 31.6 bn · 13.0% CAGR
- Biopharmaceutical LogisticsUSD 21.7 bn · 9.0% CAGR
- Pharmaceutical Cold ChainUSD 21.6 bn · 8.0% CAGR